Roivant Sciences Ltd. - Company Summary

Business Overview

Roivant Sciences Ltd. is a Bermuda-incorporated biopharmaceutical company focused on accelerating the development and commercialization of innovative medicines to improve patient lives. The company leverages a distinctive "Vant" subsidiary model to develop therapeutics across multiple immune-mediated and rare disease indications.

Core Operations & Pipeline

• Develops small molecule inhibitors, monoclonal antibodies, inhaled therapies, and nucleic acid delivery technologies.
• Utilizes proprietary computational and drug discovery technologies to build and advance medicines rapidly.
• Creates autonomous subsidiaries ("Vants") to develop and commercialize specific drug candidates, aligning incentives and enabling quick decision-making.
• Centralized capital allocation enables strategic deployment of resources across diversified pipeline projects.

Key Product Candidates & Indications

• Brepocitinib: Small molecule TYK2/JAK1 inhibitor for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.
• IMVT-1402 & Batoclimab: Fully human monoclonal antibodies targeting FcRn, in development for autoimmune diseases such as Graves’ disease, myasthenia gravis, Sjögren’s disease, and other IgG-mediated conditions.
• Mosliciguat: Inhaled soluble guanylate cyclase activator targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• Genevant Technologies: Focuses on nucleic acid delivery platforms (LNP and ligand conjugates) for RNA and gene therapies, with multiple ongoing collaborations and patent estate.
• Pulmovant: Developing mosliciguat for cardiopulmonary diseases, particularly PH-ILD.
• Immunovant: Developing IMVT-1402 and batoclimab, with multiple indications including Graves’ disease, autoimmune neurological and rheumatologic conditions, and dermatologic diseases.

Strategic Approach

• Execute through independently managed Vant subsidiaries with incentivized management teams.
• Prioritize high-probability, high-impact development programs through rigorous internal decision frameworks.
• Build a diversified pipeline across therapeutic areas, stages of development, and geographies to manage scientific and regulatory risks.
• Use proprietary technologies in drug discovery, delivery, and clinical development to accelerate timelines and improve outcomes.
• Engage in strategic licensing and partnerships, notably with Pfizer and HanAll, to access patents and technology.
• Maintain a strong balance sheet, with recent significant share repurchases totaling $1.3 billion, and divestments such as the sale of Dermavant to Organon for up to $1.2 billion.

Financial Highlights (as of fiscal year ending March 31, 2025)

• Market Capitalization: Approximate $8.1 billion based on September 30, 2024 market closing price of $11.54 per share.
• Shares Outstanding: 679,806,070 as of May 21, 2025.
• Revenue & Income: Specific revenue and net income figures are not provided in the summary.

Corporate Structure & Ownership

• The company owns varying significant stakes in subsidiaries, including:
  • Priovant: 75% (basic), 67% (fully diluted)
  • Immunovant: 57% (basic), 52% (fully diluted)
  • Pulmovant: 100% (basic), 92% (fully diluted)
  • Genevant: 83% (basic), 64% (fully diluted)
• Recently completed a notable transaction selling Dermavant to Organon, receiving ~$183.6 million upfront and milestone royalties, including future payments up to $950 million based on sales milestones.

Recent Achievements & Near-term Catalysts

• FDA approvals and large Phase 3 studies across pipeline candidates.
• Progress in patent litigation against Moderna and Pfizer/BioNTech.
• Data readouts anticipated from multiple ongoing pivotal trials through 2025–2028.

Note: Specific revenue, net income, and customer data are not provided in the given information.